Drugs that lower circulating glucose and insulin levels, in particular metformin and SGLT2 inhibitors, have been proposed as treatments for breast cancer and could potentially synergise with ET by reducing PI3K–AKT–mTOR signalling (Fig. 2) [99, 100]. Here, AKT1 is linked to breast cancer.